Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Kv7/M-type potassium channels in rat skin keratinocytes.

Reilly JM, Telezhkin V, Passmore GM, Marsh SJ, Brown DA.

Pflugers Arch. 2013 Sep;465(9):1371-81. doi: 10.1007/s00424-013-1276-2. Epub 2013 Apr 17.

2.
3.

Bimodal effects of the Kv7 channel activator retigabine on vascular K+ currents.

Yeung S, Schwake M, Pucovský V, Greenwood Ia.

Br J Pharmacol. 2008 Sep;155(1):62-72. doi: 10.1038/bjp.2008.231. Epub 2008 Jun 9.

4.

Effects of KCNQ2 gene truncation on M-type Kv7 potassium currents.

Robbins J, Passmore GM, Abogadie FC, Reilly JM, Brown DA.

PLoS One. 2013 Aug 20;8(8):e71809. doi: 10.1371/journal.pone.0071809. eCollection 2013.

5.

Vascular KCNQ (Kv7) potassium channels as common signaling intermediates and therapeutic targets in cerebral vasospasm.

Mani BK, O'Dowd J, Kumar L, Brueggemann LI, Ross M, Byron KL.

J Cardiovasc Pharmacol. 2013 Jan;61(1):51-62. doi: 10.1097/FJC.0b013e3182771708.

6.

Kv7/KCNQ/M-channels in rat glutamatergic hippocampal axons and their role in regulation of excitability and transmitter release.

Vervaeke K, Gu N, Agdestein C, Hu H, Storm JF.

J Physiol. 2006 Oct 1;576(Pt 1):235-56. Epub 2006 Jul 13.

7.

KCNQ (Kv7) potassium channel activators as bronchodilators: combination with a β2-adrenergic agonist enhances relaxation of rat airways.

Brueggemann LI, Haick JM, Neuburg S, Tate S, Randhawa D, Cribbs LL, Byron KL.

Am J Physiol Lung Cell Mol Physiol. 2014 Mar 15;306(6):L476-86. doi: 10.1152/ajplung.00253.2013. Epub 2014 Jan 17.

9.

Discovery of a retigabine derivative that inhibits KCNQ2 potassium channels.

Hu HN, Zhou PZ, Chen F, Li M, Nan FJ, Gao ZB.

Acta Pharmacol Sin. 2013 Oct;34(10):1359-66. doi: 10.1038/aps.2013.79. Epub 2013 Aug 12.

10.

Suppression of KCNQ/M (Kv7) potassium channels in dorsal root ganglion neurons contributes to the development of bone cancer pain in a rat model.

Zheng Q, Fang D, Liu M, Cai J, Wan Y, Han JS, Xing GG.

Pain. 2013 Mar;154(3):434-48. doi: 10.1016/j.pain.2012.12.005. Epub 2012 Dec 20.

PMID:
23352759
11.

An osmosensitive voltage-gated K+ current in rat supraoptic neurons.

Zhang W, Wang D, Liu XH, Kosala WR, Rajapaksha JS, Fisher TE.

Eur J Neurosci. 2009 Jun;29(12):2335-46. doi: 10.1111/j.1460-9568.2009.06772.x. Epub 2009 May 22. Erratum in: Eur J Neurosci. 2009 Aug;30(3):535.

PMID:
19490083
12.

KCNQ/M-currents contribute to the resting membrane potential in rat visceral sensory neurons.

Wladyka CL, Kunze DL.

J Physiol. 2006 Aug 15;575(Pt 1):175-89. Epub 2006 Jun 15.

13.

Inhibition of Kv7/M Channel Currents by the Local Anesthetic Chloroprocaine.

Zhang F, Cheng Y, Li H, Jia Q, Zhang H, Zhao S.

Pharmacology. 2015;96(3-4):124-30. doi: 10.1159/000437231. Epub 2015 Jul 22.

PMID:
26202459
14.

Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.

Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA.

Mol Pharmacol. 2000 Aug;58(2):253-62.

15.

M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals.

Martire M, Castaldo P, D'Amico M, Preziosi P, Annunziato L, Taglialatela M.

J Neurosci. 2004 Jan 21;24(3):592-7.

16.

KCNQ/M currents in sensory neurons: significance for pain therapy.

Passmore GM, Selyanko AA, Mistry M, Al-Qatari M, Marsh SJ, Matthews EA, Dickenson AH, Brown TA, Burbidge SA, Main M, Brown DA.

J Neurosci. 2003 Aug 6;23(18):7227-36.

17.

The pharmacological effect of positive KCNQ (Kv7) modulators on dopamine release from striatal slices.

Jensen MM, Lange SC, Thomsen MS, Hansen HH, Mikkelsen JD.

Basic Clin Pharmacol Toxicol. 2011 Nov;109(5):339-42. doi: 10.1111/j.1742-7843.2011.00730.x. Epub 2011 Jun 25.

18.

The facilitating effect of systemic administration of Kv7/M channel blocker XE991 on LTP induction in the hippocampal CA1 area independent of muscarinic activation.

Song MK, Cui YY, Zhang WW, Zhu L, Lu Y, Chen HZ.

Neurosci Lett. 2009 Sep 11;461(1):25-9. doi: 10.1016/j.neulet.2009.05.042. Epub 2009 May 20.

PMID:
19463897
19.

Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder.

Rode F, Svalø J, Sheykhzade M, Rønn LC.

Eur J Pharmacol. 2010 Jul 25;638(1-3):121-7. doi: 10.1016/j.ejphar.2010.03.050. Epub 2010 Apr 10.

PMID:
20385123
20.

A dietary agonist of transient receptor potential cation channel V3 elicits endothelium-dependent vasodilation.

Earley S, Gonzales AL, Garcia ZI.

Mol Pharmacol. 2010 Apr;77(4):612-20. doi: 10.1124/mol.109.060715. Epub 2010 Jan 19.

Items per page

Supplemental Content

Write to the Help Desk